Aardvark Therapeutics, Inc. (Aardvark), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of ...

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene ...

CG Oncology, Inc. (CGON – Research Report) received a Buy rating and price target from TD Cowen analyst Tyler Van Buren today. The company’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Get a summary of the Sale Sharks vs Clermont Auvergne, European Rugby Champions Cup 2015 18 Jan, 2015 rugby match.

We asked 10 investing and economic experts for their recommendations as Donald Trump returns to power. Here’s what they said.

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML).

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) rose 2.5% during trading on Friday . The stock traded as high as $29.90 and last traded at $29.85. Approximately 328,509 shares changed ...